Chiloiro Giuditta, Boldrini Luca, Preziosi Francesco, Cusumano Davide, Yadav Poonam, Romano Angela, Placidi Lorenzo, Lenkowicz Jacopo, Dinapoli Nicola, Bassetti Michael F, Gambacorta Maria Antonietta, Valentini Vincenzo
Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Front Oncol. 2022 Feb 24;12:831712. doi: 10.3389/fonc.2022.831712. eCollection 2022.
Distant metastasis is the main cause of treatment failure in locally advanced rectal cancer (LARC) patients, despite the recent improvement in treatment strategies. This study aims to evaluate the "delta radiomics" approach in patients undergoing neoadjuvant chemoradiotherapy (nCRT) treated with 0.35-T magnetic resonance-guided radiotherapy (MRgRT), developing a logistic regression model able to predict 2-year disease-free-survival (2yDFS).
Patients affected by LARC were enrolled in this multi-institutional study. A predictive model of 2yDFS was developed taking into account both clinical and radiomics variables. Gross tumour volume (GTV) was delineated on the magnetic resonance (MR) images acquired during MRgRT, and 1,067 radiomic features (RF) were extracted using the MODDICOM platform. The performance of RF in predicting 2yDFS was investigated in terms of the Wilcoxon-Mann-Whitney test and area under receiver operating characteristic (ROC) curve (AUC).
48 patients have been retrospectively enrolled, with 8 patients (16.7%) developing distant metastases at the 2-year follow-up. A total of 1,099 variables (1,067 RF and 32 clinical variables) were evaluated in two different models: radiomics and radiomics/clinical. The best-performing 2yDFS predictive model was a delta radiomics one, based on the variation in terms of area/surface ratio between biologically effective doses (BED) at 54 Gy and simulation (AUC of 0.92).
The results of this study suggest a promising role of delta radiomics analysis on 0.35-T MR images in predicting 2yDFS for LARC patients. Further analyses including larger cohorts of patients and an external validation are needed to confirm these preliminary results.
尽管近期治疗策略有所改进,但远处转移仍是局部晚期直肠癌(LARC)患者治疗失败的主要原因。本研究旨在评估“增量放射组学”方法在接受新辅助放化疗(nCRT)并采用0.35-T磁共振引导放疗(MRgRT)的患者中的应用,建立一个能够预测2年无病生存率(2yDFS)的逻辑回归模型。
本多机构研究纳入了LARC患者。建立了一个考虑临床和放射组学变量的2yDFS预测模型。在MRgRT期间采集的磁共振(MR)图像上勾画大体肿瘤体积(GTV),并使用MODDICOM平台提取1067个放射组学特征(RF)。通过Wilcoxon-Mann-Whitney检验和受试者操作特征曲线(ROC)下面积(AUC)研究RF在预测2yDFS方面的性能。
回顾性纳入了48例患者,其中8例(16.7%)在2年随访时发生远处转移。在两个不同模型中评估了总共1099个变量(1067个RF和32个临床变量):放射组学模型和放射组学/临床模型。表现最佳的2yDFS预测模型是基于54 Gy生物等效剂量(BED)与模拟之间面积/表面积比变化的增量放射组学模型(AUC为0.92)。
本研究结果表明,增量放射组学分析在0.35-T MR图像上对LARC患者预测2yDFS具有潜在作用。需要进一步分析,包括纳入更大规模的患者队列并进行外部验证,以证实这些初步结果。